QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bioxcel-therapeutics-announced-results-from-the-correlation-study-related-to-exploratory-efficacy-outcomes-from-serenity-at-home-trial-the-results-along-with-the-data-from-the-serenity-at-home-trial-will-be-included-in-the-supplemental-new-drug-application-submission-planned-for-1q26

The standard method for measuring acute agitation associated with schizophrenia and bipolar disorder is the Positive and Negati...

 hc-wainwright--co-reiterates-buy-on-bioxcel-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

 mizuho-maintains-neutral-on-bioxcel-therapeutics-raises-price-target-to-4

Mizuho analyst Graig Suvannavejh maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Neutral and raises the price target fro...

 bioxcel-drug-calms-agitation-at-home-for-schizophrenia-bipolar-patients

BioXcel's Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its a...

 bioxcel-therapeutics-announced-topline-exploratory-efficacy-data-from-serenity-at-home-pivotal-phase-3-safety-trial-which-demonstrated-bxcl501-had-continued-effects-and-consistent-benefit-with-repeat-dosing-for-agitation-associated-with-bipolar-disorders-or-schizophrenia

BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 tre...

 hc-wainwright--co-reiterates-buy-on-bioxcel-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

 bioxcel-seeks-fda-label-expansion-for-schizophrenia-treatment

BioXcel's Phase 3 trial shows BXCL501 safely reduces agitation in schizophrenia patients, supporting plans for an FDA label...

 bioxcel-eyes-q1-2026-snda-for-igalmi-at-home-use-following-bxcl501-phase-3-trial-results

Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 i...

 bioxcel-therapeutics-says-bxcl501-meets-primary-endpoint-in-serenity-at-home-trial-for-bipolar-and-schizophrenia-agitation

BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes...

 bioxcel-stock-surges-19-in-after-hours-trading-what-you-need-to-know

BioXcel Therapeutics shares surged over 19% after hours ahead of key Phase 3 trial results for its at-home agitation treatment,...

 bioxcel-to-reveal-phase-3-data-for-at-home-agitation-treatment-bxcl501-in-investor-call-on-august-27

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformati...

 bioxcel-reaches-key-milestone-in-phase-3-trial-for-at-home-agitation-treatment-results-coming-in-august

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformati...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION